Aviv Pudipeddi

Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial

Matthew C. Choy, C Li Wai Suen, Danny Con et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 40 citations

Inflammation, Anti-inflammatory, Gastroenterology +2

Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study

Aviv Pudipeddi, Yanna Ko, Sudarshan Paramsothy et al. · Therapeutic Advances in Gastroenterology · 2022 · 35 citations · Full text

High prevalence of Crohn disease and ulcerative colitis among older people in Sydney

Aviv Pudipeddi, Jeffrey Liu, Viraj C. Kariyawasam et al. · The Medical Journal of Australia · 2021 · 21 citations · Full text

Gastroenterologists’ preference and risk perception on the use of immunomodulators and biological therapies in elderly patients with ulcerative colitis: an international survey

Webber Chan, Viraj C. Kariyawasam, Shin Kim et al. · European Journal of Gastroenterology & Hepatology · 2020 · 18 citations · Full text

Serological Epithelial Component Proteins Identify Intestinal Complications in Crohn's Disease

Yunki Yau, Rupert W. Leong, Aviv Pudipeddi et al. · Molecular & Cellular Proteomics · 2017 · 17 citations · Full text